Whether you’re just starting psoriasis treatment or are looking for more effective therapies for your symptoms, it helps to remember these important steps to take — and to avoid. If you’re ...

Arcutis Biotherapeutics, Inc.’s ARQT share price has surged by 12.31%, which has investors questioning if this is right time to sell.

Arcutis is a rare topical dermatology player with accelerating launch metrics and continued growth. Read more about the ...

A second poster presentation shares results from the Phase 3 ARRECTOR trial that outlines improvements in patient-reported outcomes with investigational ZORYVE foam 0.3% compared with vehicle in ...

The investigational ZORYVE foam 0.3% shows significant improvements in patient-reported quality of life and symptom relief for individuals with psoriasis, indicating its potential as a valuable ...

Poster Number 62155 Roflumilast Foam 0.3% in Patients With Scalp and Body Psoriasis: Improvements in Patient-Reported Outcomes (ARRECTOR) Gooderham, M et al. ZORYVE cream, 0.3%, is indicated for ...

ZORYVE foam significantly improved quality ... Individuals reported an improvement in symptoms as well as a reduction in how psoriasis impacted their daily life (e.g., embarrassment, stress ...

ZORYVE cream, 0.3%, is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 6 years of age and older. ZORYVE cream, 0.15% ...

Optimizing use of topical agents begins with defining "mild or moderate." Clinical trials in psoriasis employ objective measures, particularly the Psoriasis Area and Severity Inde ...